vTv Therapeutics (VTVT) boosts cash, advances Phase 3 CATT1 trial
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
vTv Therapeutics Inc. reported fourth quarter and full year 2025 results and provided a clinical and corporate update. Cash and cash equivalents were $88.9 million as of December 31, 2025, up from $36.7 million a year earlier, mainly from prior private financing.
For 2025, research and development expenses rose to $17.9 million and general and administrative expenses to $14.9 million. Net loss attributable to vTv shareholders was $27.0 million, or $3.20 per basic share.
The company received a $20.0 million upfront payment in February 2026 from an amended global license with Newsoara for PDE4 inhibitor HPP737, with potential future milestones and royalties. vTv expects to complete enrollment in the CATT1 Phase 3 trial of cadisegliatin for type 1 diabetes in the third quarter of 2026 and states that its strengthened balance sheet funds operations well past the anticipated Phase 3 topline readout.
Positive
- None.
Negative
- None.
Insights
vTv strengthened its cash position while increasing R&D spend to advance late-stage diabetes programs.
vTv Therapeutics ended 2025 with cash of
Full-year research and development expenses rose to
The CATT1 Phase 3 trial for type 1 diabetes is expected to complete enrollment in the
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): March 10, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File No.) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices)
(336 ) 841-0300
(Registrant’s telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02 Results of Operations and Financial Condition
On March 10, 2026, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits
| Exhibit No. | Description | |||||||
| 99.1 | Press Release dated March 10 2026, announcing financial results for the fiscal year ended December 31, 2025 | |||||||
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| VTV THERAPEUTICS INC. | |||||||||||
| By: | /s/ Paul J. Sekhri | ||||||||||
| Name: | Paul J. Sekhri | ||||||||||
| Title: | President and Chief Executive Officer | ||||||||||
Dated: March 10, 2026
Exhibit 99.1
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement
Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026
Strengthened balance sheet provides funding runway well past the anticipated CATT1 Phase 3 topline readout
HIGH POINT, N.C., March 10, 2026 (GLOBE NEWSWIRE) – vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided an update on recent corporate developments.
“In 2025, vTv delivered meaningful clinical and corporate progress that positions us for a highly productive 2026,” said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics. “During the course of the year, we initiated patient dosing in the Phase 3 CATT1 trial evaluating cadisegliatin as an adjunct to insulin for the treatment of type 1 diabetes, strengthened our balance sheet with an $80.0 million financing with leading healthcare investors, and continued to expand our intellectual property estate supporting cadisegliatin. In early 2026, we secured an additional $20.0 million in non-dilutive funding.”
“Looking ahead, 2026 remains an important year for vTv as we advance the CATT1 Phase 3 trial. Following study start-up, while patient enrollment progressed more slowly than initially anticipated, we expanded the number of participating sites, and increased physician and patient engagement efforts, resulting in a significant acceleration in enrollment momentum. Based on current trends, we expect to complete enrollment in the third quarter of 2026. Cadisegliatin continues to show promise as a meaningful oral adjunctive therapy for people living with type 1 diabetes, and we look forward to completing the trial and bringing this important potential therapy to market.”
Recent Company Highlights
•Amended Licensing Agreement with Newsoara Biopharma Inc., Resulting in $20.0 million Upfront Milestone Payment to vTv. In February 2026, the Company announced it expanded its license agreement with Newsoara to include global rights to the Company’s highly selective PDE4 inhibitor, HPP737. Pursuant to the amended license agreement, Newsoara obtained an exclusive, worldwide license to develop and commercialize Company’s PDE4 inhibitor, HPP737, in exchange for vTv receiving an upfront payment of $20.0 million, as well as the potential to receive future development milestones of up to approximately $50.0 million, sales milestones of up to $65.0 million, and tiered royalties based on sales.
•Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health. In December 2025, vTv and M42’s Insights Research Organization & Solutions (IROS) announced that a Phase 2 clinical study protocol was submitted to the Department of Health (DOH) Abu Dhabi. The study is designed to evaluate the safety and efficacy of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin, in people living with type 2 diabetes.
•New Appointments to its Scientific Advisory Board. In October 2025, the Company announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein,
MD, PhD, to its Scientific Advisory Board (SAB). The SAB, composed of internationally recognized leaders in endocrinology, diabetes research, clinical trial design, and regulatory science, will continue providing strategic guidance on the development of cadisegliatin, which is currently being investigated in Phase 3 clinical trials as an oral adjunctive therapy to insulin for the treatment of T1D.
Fourth Quarter 2025 Financial Results
•Cash Position: The Company’s cash position as of December 31, 2025, was $88.9 million compared to $36.7 million as of December 31, 2024. This increase is largely due to proceeds from the private placement financing as announced on September 2, 2025.
•Research & Development (R&D) Expenses: R&D expenses were $3.9 million and $2.2 million in each of the three months ended December 31, 2025, and 2024, respectively. The increase is attributable to (i) higher spending on cadisegliatin of $3.6 million, due to increases in clinical studies, partially offset by (ii) a decrease in indirect costs of $0.4 million, and (iii) a decrease of $1.5 million in other projects primarily related to the write off of an aged accrual.
•General & Administrative (G&A) Expenses: G&A expenses were $4.0 million and $2.7 million for each of the three months ended December 31, 2025, and 2024, respectively. The increase of $1.3 million was primarily due to (i) an increase in payroll expense of $0.3 million, (ii) an increase in legal expense of $0.3 million, (iii) an increase in share-based expense of $0.1 million, and (iv) an increase in other operating costs of $0.6 million.
•Interest Income: Interest income for the three months ended December 31, 2025 and December 31, 2024 of $0.9 million and $0.4 million, respectively, is related to interest and dividend income from our money market account.
•Other (Expense) Income, net: Other expense of $0.1 million for the three months ended December 31, 2025 was driven by losses related to the change in the fair value of the outstanding warrants to purchase our Class A common stock. Other income for the three months ended December 31, 2024 was immaterial.
•Net Loss: Net loss attributable to vTv shareholders for the three months ended December 31, 2025, was $7.1 million or $0.58 per basic share. Net loss attributable to vTv shareholders for the comparable period a year ago was $3.6 million or $0.55 per basic share.
Full Year 2025 Financial Results
•Research & Development (R&D) Expenses: R&D expenses were $17.9 million and $11.5 million in each of the years ended December 31, 2025, and 2024, respectively. The increase is attributable to (i) higher spending on cadisegliatin of $5.4 million, due to increases in clinical studies, (ii) an increase in indirect costs of $2.6 million primarily due to increases in payroll and bonus costs and a $1.0 million Novo license milestone payment, partially offset by (iii) a decrease of $1.7 million in other projects primarily related to the write off of an aged accrual.
•General & Administrative (G&A) Expenses: G&A expenses were $14.9 million and $13.7 million for each of the years ended December 31, 2025, and 2024, respectively. The increase of $1.3 million was due to (i) an increase in share-based expense of $0.6 million, (ii) an increase in payroll costs of $0.4 million, (iii) an increase in legal expenses of $0.2 million, and (iv) an increase in other operating costs of $0.1 million.
•Interest Income: Interest income for the years ended December 31, 2025 and December 31, 2024 of $1.9 million and $1.6 million, respectively, is related to interest and dividend income from our money market account.
•Other (Expense) Income, net: Other expense of $0.1 million for the year ended December 31, 2025 was driven by losses related to the change in the fair value of the outstanding warrants to purchase our Class A common stock. Other income for the year ended December 31, 2024 was immaterial.
•Net Loss: Net loss attributable to vTv shareholders for the year ended December 31, 2025, was $27.0 million or $3.20 per basic share. Net loss attributable to vTv shareholders for the comparable period a year ago was $18.5 million or $3.20 per basic share.
vTv Therapeutics Inc.
Condensed Consolidated Balance Sheets
(in thousands)
| December 31, 2025 | December 31, 2024 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 88,932 | $ | 36,746 | |||||||
| Prepaid expenses | 743 | 1,192 | |||||||||
| Other current assets | 218 | 175 | |||||||||
| Total current assets | 89,893 | 38,113 | |||||||||
| Other assets | 6 | 153 | |||||||||
| Total assets | $ | 89,899 | $ | 38,266 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable and accrued expenses | $ | 6,557 | $ | 5,027 | |||||||
| Current portion of operating lease liabilities | — | 169 | |||||||||
| Warrant liability, related party | 84 | — | |||||||||
| Total current liabilities | 6,641 | 5,196 | |||||||||
| Contract liabilities, net of current portion | 18,669 | 18,669 | |||||||||
| Warrant liability, related party | — | 57 | |||||||||
| Warrant liability | 152 | 43 | |||||||||
| Total liabilities | 25,462 | 23,965 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
Class A Common Stock | 39 | 26 | |||||||||
Class B Common Stock | — | 6 | |||||||||
| Additional paid-in capital | 391,090 | 311,885 | |||||||||
| Accumulated deficit | (326,692) | (299,718) | |||||||||
| Total stockholders’ equity attributable to vTv Therapeutics Inc. | 64,437 | 12,199 | |||||||||
| Noncontrolling interest | — | 2,102 | |||||||||
| Total stockholders’ equity | 64,437 | 14,301 | |||||||||
| Total liabilities, redeemable noncontrolling interest and stockholders’ equity | $ | 89,899 | $ | 38,266 | |||||||
vTv Therapeutics Inc.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
Three Months Ended December 31, | For the Year Ended December 31, | ||||||||||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| (Unaudited) | |||||||||||||||||||||||
| Revenue | $ | — | $ | 17 | $ | — | $ | 1,017 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 3,908 | 2,234 | 17,861 | 11,546 | |||||||||||||||||||
| General and administrative | 3,977 | 2,675 | 14,947 | 13,651 | |||||||||||||||||||
| Total operating expenses | 7,885 | 4,909 | 32,808 | 25,197 | |||||||||||||||||||
| Operating loss | (7,885) | (4,892) | (32,808) | (24,180) | |||||||||||||||||||
| Interest income | 865 | 429 | 1,870 | 1,565 | |||||||||||||||||||
| Interest expense | (1) | — | (6) | — | |||||||||||||||||||
Other (expense) income, net | (117) | 26 | (136) | 10 | |||||||||||||||||||
| Loss before income taxes | (7,138) | (4,437) | (31,080) | (22,605) | |||||||||||||||||||
| Income tax provision | — | — | — | 100 | |||||||||||||||||||
| Net loss before noncontrolling interest | (7,138) | (4,437) | (31,080) | (22,705) | |||||||||||||||||||
| Less: Net loss attributable to noncontrolling interest | — | (803) | (4,106) | (4,243) | |||||||||||||||||||
| Net loss attributable to vTv Therapeutics Inc. | $ | (7,138) | $ | (3,634) | $ | (26,974) | $ | (18,462) | |||||||||||||||
| Net loss attributable to vTv Therapeutics Inc. common shareholders | $ | (7,138) | $ | (3,634) | $ | (26,974) | $ | (18,462) | |||||||||||||||
| Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted | $ | (0.58) | $ | (0.55) | $ | (3.20) | $ | (3.20) | |||||||||||||||
| Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted | 12,408,696 | 6,582,844 | 8,423,632 | 5,771,052 | |||||||||||||||||||
About Cadisegliatin
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the US as a potential first-in-class oral adjunctive treatment for type 1 diabetes (T1D). In non-clinical studies, cadisegliatin, acting selectively on the liver, increased the activity of glucokinase independently from insulin which supports clinical investigation of improvement in glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).
Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.
About vTv Therapeutics
vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv’s clinical pipeline is led by cadisegliatin, currently in a US Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of type 1 diabetes. vTv and its development partners are investigating multiple molecules across different indications for chronic diseases. Learn more at vtvtherapeutics.com or follow the company on LinkedIn or X.
Forward-Looking Statement
This release contains forward-looking statements, which involve risks and uncertainties. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and, in each case, their negative or other various or comparable terminology. All statements other than statements of historical facts contained in this release, including statements regarding the satisfaction of the closing conditions set forth in the securities purchase
agreement, the expected use of proceeds from the offering, the timing of our clinical trials, the anticipated effect of Phase 3 topline data on the Company, the benefits of cadisegliatin to people living with T1D, our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause our results to vary from expectations include those described under the heading “Risk Factors” in our Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and our other filings with the SEC. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this release. We anticipate that subsequent events and developments will cause our views to change. Our forward-looking statements do not reflect the potential impact of any future acquisitions, merger, dispositions, joint ventures, or investments we may undertake. We qualify all our forward-looking statements by these cautionary statements.
Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Media Contact
Caren Begun
TellMed Strategies
201-396-8551
caren.begun@tmstrat.com
FAQ
What were vTv Therapeutics (VTVT) full year 2025 financial results?
vTv reported a 2025 net loss attributable to shareholders of $27.0 million, or $3.20 per basic share. Research and development expenses were $17.9 million and general and administrative expenses were $14.9 million, reflecting higher spending on cadisegliatin clinical trials and corporate costs.
What is vTv Therapeutics’ cash position as of December 31, 2025?
As of December 31, 2025, vTv held $88.9 million in cash and cash equivalents, up from $36.7 million a year earlier. The increase mainly reflects proceeds from a private placement completed in 2025, providing a funding runway well past the anticipated CATT1 Phase 3 topline readout.
What did vTv Therapeutics announce about the Newsoara licensing agreement?
In February 2026, vTv expanded its license with Newsoara Biopharma Inc. to grant global rights to PDE4 inhibitor HPP737. vTv received a $20.0 million upfront payment and may receive up to approximately $50.0 million in development milestones, $65.0 million in sales milestones, plus tiered sales royalties.
What is the status of vTv’s CATT1 Phase 3 trial for cadisegliatin?
vTv is conducting the CATT1 Phase 3 trial of cadisegliatin as an oral adjunctive therapy to insulin for type 1 diabetes. After initially slower enrollment, additional sites and engagement improved momentum, and the company expects to complete enrollment in the third quarter of 2026 based on current trends.
How did vTv Therapeutics’ R&D and G&A expenses change in 2025?
In 2025, research and development expenses increased to $17.9 million from $11.5 million, driven by higher cadisegliatin clinical spending and a Novo license milestone. General and administrative expenses rose to $14.9 million from $13.7 million, mainly from higher share-based compensation, payroll, and legal costs.
What is cadisegliatin and how is it being developed by vTv Therapeutics?
Cadisegliatin (TTP399) is a liver-selective glucokinase activator being investigated as a first-in-class oral adjunctive treatment for type 1 diabetes. It has FDA Breakthrough Therapy designation and is currently in a U.S. Phase 3 trial, with additional Phase 2 work planned in type 2 diabetes.
How did vTv’s balance sheet and equity position change during 2025?
Total assets increased to $89.9 million at December 31, 2025, from $38.3 million a year earlier, largely from higher cash. Total stockholders’ equity attributable to vTv rose to $64.4 million from $12.2 million, reflecting new capital raised and changes in noncontrolling interests.
Filing Exhibits & Attachments
4 documents
Vtv Therapeutics
NASDAQ:VTVT
VTVT Rankings
VTVT Latest News
VTVT Latest SEC Filings
Mar 10, 2026
[8-K] vTv Therapeutics Inc. Reports Material Event
Mar 10, 2026
[10-K] vTv Therapeutics Inc. Files Annual Report
Feb 26, 2026
[8-K] vTv Therapeutics Inc. Reports Material Event